Investigational Drug for Scleroderma-associated PAH

Trial Objective

The purpose of this study is to determine if a new investigational medication, Tecfidera®, helps people with systemic sclerosis-associated pulmonary arterial hypertension (PAH). Tecfidera is currently FDA approved for use in patients with multiple sclerosis.

Investigational Drug for Scleroderma-associated PAH

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Kris Eliopoulos at 303.270.2622 or complete the form below.

Who Can Participate

Individuals ages 18-80 who have systemic sclerosis-associated pulmonary arterial hypertension and are currently on stable medical therapies for PAH.


Estimated Time Commitment

6 visits over 40 weeks

Two telephone visits at weeks 1 and 4. Approximately 20 hours total.

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

National Institutes of Health (NIH)

Age

18-80


Gender

Any Gender

Principal Investigators


Request More Information

*
*
*
*